Corbus Pharmaceuticals (CRBP) Earnings Date, Estimates & Call Transcripts $9.13 -0.12 (-1.30%) Closing price 08/19/2025 04:00 PM EasternExtended Trading$9.17 +0.04 (+0.44%) As of 08/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Corbus Pharmaceuticals Earnings Summary Corbus Pharmaceuticals posted Q2 2025 earnings on August 5, 2025, reporting an EPS of -$1.44, which beat the consensus estimate of -$1.55 by $0.11. With a trailing EPS of -$4.76, Corbus Pharmaceuticals' earnings are expected to decrease next year, from ($4.23) to ($6.29) per share. Upcoming Q3 Earnings DateNov. 6Before Market OpensEstimatedConsensus EPS (Aug. 5) -$1.55 Actual EPS (Aug. 5) -$1.44 Beat By $0.11 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)CRBP Upcoming EarningsCorbus Pharmaceuticals' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules. Powered by Get Corbus Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCRBP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Corbus Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$2.74-$0.92-$1.55Q2 20255-$3.00-$0.89-$1.62Q3 20255-$3.28-$1.46-$1.89Q4 20255-$3.59-$1.09-$1.87 FY 2025 18 -$12.61 -$4.36 -$6.92 Q1 20261-$1.51-$1.51-$1.51Q2 20261-$1.49-$1.49-$1.49Q3 20261-$1.55-$1.55-$1.55Q4 20261-$1.54-$1.54-$1.54 Corbus Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/6/2025(Estimated)--------8/5/2025Q2 2025-$1.55-$1.44+$0.11-$1.44--5/6/2025Q1 2025-$1.26-$1.39 -$0.13-$1.39--3/11/2025Q4 2024-$1.02-$0.78+$0.24-$0.78--11/7/2024--$0.99-$1.15 -$0.16-$1.15--8/6/2024Q2 2024-$1.19-$0.90+$0.29-$0.90--5/7/2024Q1 2024-$1.09-$0.83+$0.26-$0.83--3/12/2024Q4 2023-$2.36-$1.81+$0.55-$1.81--11/7/2023Q3 2023-$2.06-$2.27 -$0.21-$2.27-- Corbus Pharmaceuticals Earnings - Frequently Asked Questions When is Corbus Pharmaceuticals' earnings date? Corbus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based off last year's report dates. Learn more on CRBP's earnings history. Did Corbus Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Corbus Pharmaceuticals (NASDAQ:CRBP) reported ($1.44) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.55) by $0.11. Learn more on analysts' earnings estimate vs. CRBP's actual earnings. How much profit does Corbus Pharmaceuticals generate each year? Corbus Pharmaceuticals (NASDAQ:CRBP) has a recorded net income of -$40.21 million. CRBP has generated -$4.76 earnings per share over the last four quarters. What is Corbus Pharmaceuticals' EPS forecast for next year? Corbus Pharmaceuticals' earnings are expected to decrease from ($4.23) per share to ($6.29) per share in the next year. More Earnings Resources from MarketBeat Related Companies REPL Earnings KMDA Earnings GOSS Earnings ERAS Earnings RGNX Earnings AQST Earnings YMAB Earnings HUMA Earnings VIGL Earnings CYRX Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles DLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals? This page (NASDAQ:CRBP) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWinning the AI WarWhat’s really driving the trade wars, reshoring, and sweeping executive orders? According to Porter Stansberry...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access